Dark

Check out our Level2View

CEREW
Cerevel Therapeutics Holdings, Inc. Warrant
stock NASDAQ

Inactive

Aug 30, 2021

18.07USD-3.266%(-0.61)406

Pre-market

0.00USD-100.000%(-18.68)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 10, 2022

06:30AM EST Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia GlobeNewswire Inc

Jan 3, 2022

07:00AM EST Cerevel to Present at the 40th Annual J.P. Morgan Healthcare GlobeNewswire Inc

Dec 16, 2021

07:00AM EST Cerevel Therapeutics and Herophilus Announce Collaboration to GlobeNewswire Inc

Nov 10, 2021

06:30AM EST Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022 GlobeNewswire Inc

Nov 1, 2021

06:30AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that it will participate in four upcoming virtual investor conferences during the months of November and December. GlobeNewswire Inc

Oct 20, 2021

06:30AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report third quarter 2021 financial results and pipeline updates on Wednesday, November 10, 2021, before the U.S. financial markets open. GlobeNewswire Inc

Oct 7, 2021

07:00AM EDT Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in GlobeNewswire Inc

Sep 21, 2021

05:00PM EDT Current Chief Accounting Officer Mark Bodenrader named as interim CFO GlobeNewswire Inc

Sep 10, 2021

07:00AM EDT Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophrenia GlobeNewswire Inc

Sep 1, 2021

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that members of the management team will participate in two upcoming virtual investor conferences during the month of September. GlobeNewswire Inc

Aug 11, 2021

06:30AM EDT Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia GlobeNewswire Inc

Jul 30, 2021

07:00AM EDT Cerevel Therapeutics Announces Redemption of Public Warrants GlobeNewswire Inc

Jul 22, 2021

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report second quarter 2021 financial results and provide a pipeline update on Wednesday, August 11, 2021, before the U.S. financial markets open. GlobeNewswire Inc

Jul 1, 2021

09:50PM EDT Cerevel Therapeutics Announces Pricing of $350 Million Public GlobeNewswire Inc

Jun 29, 2021

04:24PM EDT Cerevel Therapeutics Announces Proposed Public Offering of Common GlobeNewswire Inc

06:30AM EDT Both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks and were overall well-tolerated compared with placebo GlobeNewswire Inc

Jun 15, 2021

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CVL-871, a D1/D5 partial agonist in development for the treatment of dementia-related apathy. GlobeNewswire Inc

May 27, 2021

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that it will participate in two upcoming virtual investor conferences during the month of June. GlobeNewswire Inc

May 17, 2021

06:30AM EDT Cerevel Therapeutics Reports First Quarter 2021 Financial Results GlobeNewswire Inc

May 4, 2021

07:00AM EDT Cerevel Therapeutics Announces the Appointment of Scott M. Akamine GlobeNewswire Inc

Apr 29, 2021

07:00AM EDT Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report first quarter 2021 financial results on Monday, May 17, 2021, before the U.S. financial markets open. GlobeNewswire Inc

Apr 21, 2021

07:00AM EDT Cerevel Therapeutics Appoints Abraham N. Ceesay as President GlobeNewswire Inc

Apr 13, 2021

06:30AM EDT Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinsons disease through planned NDA submission GlobeNewswire Inc

Mar 24, 2021

06:30AM EDT Data readout of Phase 1b trial of CVL-231 in patients with schizophrenia now expected mid-year 2021 GlobeNewswire Inc

Mar 22, 2021

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that Chairperson and Chief Executive Officer, Tony Coles, M.D. will participate in a fireside chat at the Stifel 3rd Annual CNS Day on Wednesday, March 31, 2021 at 9:00 a.m. EDT. GlobeNewswire Inc

Feb 24, 2021

07:00AM EST Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report fourth quarter and full year 2020 financial results on Wednesday, March 24, 2021, before the U.S. financial markets open. GlobeNewswire Inc

Feb 23, 2021

07:00AM EST Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference. GlobeNewswire Inc

Jan 28, 2021

07:00AM EST Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator GlobeNewswire Inc

Jan 21, 2021

07:00AM EST Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced today that it has appointed the Honorable Deval Patrick and Deborah Baron to serve as independent members of its Board of Directors. GlobeNewswire Inc

Dec 14, 2020

07:00AM EST Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs GlobeNewswire Inc

Dec 8, 2020

07:00AM EST Cerevel Therapeutics Announces the Appointment of Dr. Ruth GlobeNewswire Inc

Dec 4, 2020

07:00AM EST Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced it will host a live webcast providing a current corporate overview, followed by a moderated question and answer session on Monday, December 14. GlobeNewswire Inc

Nov 23, 2020

07:00AM EST Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 3:05 p.m. EST. GlobeNewswire Inc

Nov 16, 2020

06:30AM EST Participants dosed in clinical trials for lead programs in schizophrenia, epilepsy, anxiety and Parkinsons disease GlobeNewswire Inc

Nov 4, 2020

07:00AM EST Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that members of the management team will participate in three upcoming virtual investor conferences during the month of November. GlobeNewswire Inc

Oct 30, 2020

07:00AM EDT Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 GlobeNewswire Inc

Oct 28, 2020

07:00AM EDT Business combination transaction with Arya Sciences Acquisition Corp II, a special purpose acquisition company sponsored by Perceptive Advisors, completed on October 27, 2020 GlobeNewswire Inc

Share